Quick Answer
Avalo Therapeutics, Inc. reported Stockholders Equity of $83.05 million for fiscal year 2025.
Avalo Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $83.05M | -37.6% |
| 2024 | $133.03M | +1721.4% |
| 2023 | $7.30M | +166.9% |
| 2022 | -$10.91M | -147.3% |
| 2021 | $23.08M | -6.0% |
| 2020 | $24.56M | +17.0% |
| 2019 | $21.00M | +0.4% |
| 2018 | $20.91M | -25.0% |
| 2017 | $27.86M | +13358.6% |
| 2016 | $207.0K | -98.4% |
| 2015 | $13.08M | +149.7% |
| 2014 | -$26.33M | -47.5% |
| 2013 | -$17.85M | -56.8% |
| 2012 | -$11.38M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $91.55M | +334.4% | -12.5% |
| June 30, 2025 | $104.57M | +868.5% | -14.7% |
| March 31, 2025 | $122.61M | +209.0% | -7.8% |
| December 31, 2024 | $133.03M | +1721.4% | +531.2% |
| September 30, 2024 | $21.08M | +43.4% | +254.9% |
| June 30, 2024 | -$13.61M | -95.3% | +87.9% |
| March 31, 2024 | -$112.54M | -1695.8% | -1640.8% |
| December 31, 2023 | $7.30M | +166.9% | -50.3% |
- Avalo Therapeutics, Inc. showed a decrease of -37.6% in Stockholders Equity compared to the prior fiscal year.
- Over the 2012–2025 period, Avalo Therapeutics, Inc.’s stockholders equity has grown by 829.7% (from -$11.38 million to $83.05 million).
- The most recent figure is from Avalo Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: